Remaining challenges in treating solid tumors with CAR-Treg therapy [Video]

Leonardo Ferreira, PhD, The Medical University of South Carolina (MUSC), Charleston, SC, comments on barriers to clinical use of chimeric antigen receptor regulatory T (CAR-Treg) cells for solid tumors. Since Treg cells are a small subset of T-cells, procuring a suitable number of Treg cells will be a challenge, and finding a suitable target that will minimize the rate of off-target toxicities is additionally essential. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.